Scarica l'app Stockscreener
0.6258
7.30%
-0.0493
Dopo l'orario di chiusura:
.67
0.0442
+7.06%
Cue Biopharma Inc Borsa (CUE) Ultime notizie
Cue Biopharma’s SWOT analysis: strategic pivot to autoimmune diseases reshapes stock outlook - Investing.com
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Cue Biopharma (CUE) to Release Earnings on Monday - Defense World
Cue Biopharma, Inc. (NASDAQ:CUE) Shares Purchased by HighTower Advisors LLC - Defense World
Cue Biopharma Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Cue Biopharma Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cue Biopharma’s Strategic Focus and Financial Outlook - TipRanks
What's Going On With Cue Biopharma Shares Tuesday? - Benzinga
Cue Biopharma earnings missed by $0.04, revenue fell short of estimates - Investing.com Canada
Cue Biopharma, Inc. (CUE) Reports Q4 Loss, Misses Revenue Estimates - MSN
Cue Biopharma Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights - The Manila Times
Artiva Biotherapeutics Reports Full Year 2024 Financial Results and Recent Business Highlights - The Manila Times
Bleichroeder LP Increases Stake in Cue Biopharma Inc - GuruFocus.com
[Top 3] Best Biotech Penny Stocks to Buy in 2025Finbold - Finbold - Finance in Bold
Cue Biopharma (CUE) Projected to Post Quarterly Earnings on Wednesday - Defense World
Strength Seen in TG Therapeutics (TGTX): Can Its 10.2% Jump Turn into More Strength? - Nasdaq
Cue Biopharma appoints Pasha Sarraf to board By Investing.com - Investing.com Australia
Cue Biopharma Appoints Pasha Sarraf to Board - TipRanks
Cue Biopharma appoints Pasha Sarraf to board - Investing.com
Cue Biopharma (NASDAQ:CUE) Trading Down 3.8%What's Next? - MarketBeat
Larger animals really are more prone to cancer, debunking ‘Peto’s paradox’ - Study Finds
Layoff Tracker: Spotlight Goes Dark After Disappointing Preclinical Data for CRISPR Platform - BioSpace
HPV+ Recurrent/Metastatic Head and Neck Cancer Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Public Ventures LLC Completes First Public Company Financing as a Broker-Dealer for Cue Biopharma, Inc. (Nasdaq:CUE) - ACCESS Newswire
Pancreatic Adenocarcinoma Market Growth Projections - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Update - MarketBeat
Artiva Biotherapeutics expands board with industry veteran - MSN
Artiva Biotherapeutics Expands Board of Directors with Appointment of Dan Baker, M.D. - The Manila Times
Artiva Biotherapeutics appoints new director and committee members - MSN
Artiva Biotherapeutics appoints new director and committee members By Investing.com - Investing.com Nigeria
Artiva expands Board with appointment of Dan Baker, M.D - TipRanks
Former J&J Drug Development Chief Who Created Multi-Billion Dollar Therapies Joins Rising Biotech Board - StockTitan
Geode Capital Management LLC Increases Stock Position in Cue Biopharma, Inc. (NASDAQ:CUE) - Defense World
Geode Capital Management LLC Purchases 212,394 Shares of Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) - Defense World
HPV16+ Cancer Clinical and Non-Clinical Studies, Key - openPR
Cue Biopharma, Inc. (NASDAQ:CUE) Short Interest Up 8.0% in December - MarketBeat
Cue Biopharma (NASDAQ:CUE) versus FibroGen (NASDAQ:FGEN) Head-To-Head Comparison - Defense World
The definitive Boston biotech layoff tracker for 2024 - The Business Journals
Certain Common Stock of Cue Biopharma, Inc. are subject to a Lock-Up Agreement Ending on 26-DEC-2024. - Marketscreener.com
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock By Investing.com - Investing.com Australia
Cue Biopharma CEO Daniel Passeri buys $30,900 in stock - Investing.com India
Insider Buying: Daniel Passeri Acquires 30,000 Shares of Cue Bio - GuruFocus.com
Cue Biopharma, Inc. (NASDAQ:CUE) CEO Purchases $30,900.00 in Stock - MarketBeat
Short Interest in Cue Biopharma, Inc. (NASDAQ:CUE) Decreases By 6.5% - MarketBeat
Cue Biopharma's SWOT analysis: stock pivot to autoimmune focus sparks debate - Investing.com Australia
0.48%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):